John Eric Milad
Directeur Général chez ERS Genomics Ltd.
Profil
John Eric Milad is the founder of Quanta Dialysis Technologies Ltd.
(founded in 2008) where he held the title of Chief Executive Officer & Director.
He is currently the Chief Executive Officer at ERS Genomics Ltd.
(since 2024).
In the past, he has worked as a Director at Symetis SA, Investment Director at Stage Capital Ventures (in 2013), Director at BONESUPPORT HOLDING AB, Director at Cellnovo Group SA, Special Advisor at Atlas Venture LLP, CFO & Head-Business Development at Horizon Therapeutics Switzerland GmbH, and at Nomura International Plc.
He completed his undergraduate degree at The University of Chicago.
Postes actifs de John Eric Milad
| Sociétés | Poste | Début |
|---|---|---|
ERS Genomics Ltd.
 ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Directeur Général | 13/05/2024 |
Anciens postes connus de John Eric Milad
| Sociétés | Poste | Fin |
|---|---|---|
Stage Capital Ventures
 Stage Capital Ventures Investment ManagersFinance Stage Capital Ventures is a Venture Capital firm, a subsidiary of NBGI Private Equity Ltd. founded in 2000 by Aris Constantinides. Stage Capital Ventures is headquartered in Boca Raton. | Private Equity Investor | 01/12/2013 |
Atlas Venture LLP
 Atlas Venture LLP Investment ManagersFinance Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds. | Corporate Officer/Principal | - |
Quanta Dialysis Technologies Ltd.
 Quanta Dialysis Technologies Ltd. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom. | Fondateur | - |
| CELLNOVO | Directeur/Membre du Conseil | - |
| SYMETIS SA | Directeur/Membre du Conseil | - |
Formation de John Eric Milad
| The University of Chicago | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BONESUPPORT HOLDING AB | Health Technology |
| Entreprise privées | 7 |
|---|---|
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Health Technology |
Stage Capital Ventures
Stage Capital Ventures Investment ManagersFinance Stage Capital Ventures is a Venture Capital firm, a subsidiary of NBGI Private Equity Ltd. founded in 2000 by Aris Constantinides. Stage Capital Ventures is headquartered in Boca Raton. | Finance |
Symetis SA
 Symetis SA BiotechnologyHealth Technology Symetis SA develops minimally invasive heart valve replacement devices. Its products include ACURATE TA and ACURATE neo. The company was founded by Simon P. Hoerstrup and Gregor Zünd on September 5, 2001 and is headquartered in Ecublens, Switzerland. | Health Technology |
Cellnovo Group SA
 Cellnovo Group SA Medical SpecialtiesHealth Technology Cellnovo Group SA was a medical technology company, which specialized in diabetes. The company developed and marketed the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. It products portfolio included system, switch, pump therapy, and patient stories. The company was founded by Julian Shapley on December 15, 2014 and was headquartered in Paris, France. | Health Technology |
Quanta Dialysis Technologies Ltd.
Quanta Dialysis Technologies Ltd. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom. | Health Technology |
Atlas Venture LLP
Atlas Venture LLP Investment ManagersFinance Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds. | Finance |
ERS Genomics Ltd.
ERS Genomics Ltd. BiotechnologyHealth Technology ERS Genomic Ltd. engages in the development of biotechnology. It was formed to provide broad access to the foundational CRISPR-Cas9, a new genome editing technology, which offers speed, efficiency, and cost over earlier genome editing methods. The company was founded by Emmanuelle Charpentier and Shaun Foy in 2014 and is headquartered in Dublin, Ireland. | Health Technology |
